Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Voorraadrapport

Marktkapitalisatie: NT$75.7b

Lotus Pharmaceutical Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Lotus Pharmaceutical is de winst gegroeid met een gemiddeld jaarlijks percentage van 39.5%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 8.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 14% per jaar. Het rendement op eigen vermogen van Lotus Pharmaceutical is 21.4%, en het heeft een nettomarge van 24.6%.

Belangrijke informatie

39.5%

Groei van de winst

38.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie18.5%
Inkomstengroei14.0%
Rendement op eigen vermogen21.4%
Nettomarge24.6%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Recent updates

Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Opbrengsten en kosten

Hoe Lotus Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

TWSE:1795 Opbrengsten, kosten en inkomsten (TWD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 2417,5944,3334,094503
30 Jun 2416,9334,0143,972588
31 Mar 2416,6323,9483,812493
31 Dec 2316,9584,1063,760541
30 Sep 2316,7103,8733,569537
30 Jun 2317,5274,7073,452504
31 Mar 2315,9953,7693,370483
31 Dec 2214,6333,0213,138419
30 Sep 2214,2643,1052,925411
30 Jun 2211,9321,3742,792330
31 Mar 2212,4861,4012,679397
31 Dec 2112,6491,4032,738374
30 Sep 2112,9771,4702,774408
30 Jun 2112,8061,4002,736460
31 Mar 2112,0191,3442,642371
31 Dec 2010,7291,0272,472384
30 Sep 2010,8028482,379469
30 Jun 209,9337692,365431
31 Mar 209,3075192,520470
31 Dec 199,6116632,545465
30 Sep 198,1305962,455434
30 Jun 197,6934632,387375
31 Mar 197,2783592,266323
31 Dec 186,429992,232318
30 Sep 186,537382,232301
30 Jun 186,535192,198316
31 Mar 186,4771102,099313
31 Dec 176,424222,086289
30 Sep 176,072-1712,062415
30 Jun 175,897-2522,176414
31 Mar 175,913-2702,342411
31 Dec 165,903-1342,396416
30 Sep 165,896782,510316
30 Jun 165,9101262,487322
31 Mar 165,6531982,423314
31 Dec 155,5221042,481299
30 Sep 154,712-1022,405256
30 Jun 153,879-2042,137209
31 Mar 153,125-3121,845177
31 Dec 142,310-4421,458132
30 Sep 142,201-3071,169124
30 Jun 142,152-2691,10280
31 Mar 142,411-3301,19937
31 Dec 132,092-1431,00564

Kwaliteitswinsten: 1795 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (24.6%) 1795 } zijn hoger dan vorig jaar (23.2%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van 1795 is de afgelopen 5 jaar aanzienlijk gegroeid met 39.5% per jaar.

Versnelling van de groei: De winstgroei van 1795 over het afgelopen jaar ( 11.9% ) ligt onder het 5-jarig gemiddelde ( 39.5% per jaar).

Winst versus industrie: De winstgroei 1795 over het afgelopen jaar ( 11.9% ) overtrof de Pharmaceuticals -sector 11.9%.


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 21.4% ) van 1795 wordt als hoog beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden